MHLW (Japan) approves Xenpozyme to treat non CNS manifestations of acid sphingomyelinase deficiency (Niemann-Pick disease)
The Japanese Ministry of Health, Labor, and Welfare (MHLW) has granted marketing authorization for Xenpozyme (olipudase alfa) for the treatment of adult and pediatric patients with non-central nervous system (non-CNS) manifestations of acid sphingomyelinase deficiency (ASMD), a rare, progressive, and potentially life-threatening genetic disease.